CN108697727A - 治疗和预防hiv和aids的方法 - Google Patents

治疗和预防hiv和aids的方法 Download PDF

Info

Publication number
CN108697727A
CN108697727A CN201780010879.XA CN201780010879A CN108697727A CN 108697727 A CN108697727 A CN 108697727A CN 201780010879 A CN201780010879 A CN 201780010879A CN 108697727 A CN108697727 A CN 108697727A
Authority
CN
China
Prior art keywords
hiv
administered
efda
once
dosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780010879.XA
Other languages
English (en)
Chinese (zh)
Inventor
D.哈祖达
M.D.米勒
J.A.格罗布勒
D.A.尼科尔格里夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Priority to CN202110783129.4A priority Critical patent/CN113509480A/zh
Publication of CN108697727A publication Critical patent/CN108697727A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
CN201780010879.XA 2016-02-12 2017-02-10 治疗和预防hiv和aids的方法 Pending CN108697727A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110783129.4A CN113509480A (zh) 2016-02-12 2017-02-10 治疗和预防hiv和aids的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US62/294576 2016-02-12
US201662297657P 2016-02-19 2016-02-19
US62/297657 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110783129.4A Division CN113509480A (zh) 2016-02-12 2017-02-10 治疗和预防hiv和aids的方法

Publications (1)

Publication Number Publication Date
CN108697727A true CN108697727A (zh) 2018-10-23

Family

ID=58057333

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780010879.XA Pending CN108697727A (zh) 2016-02-12 2017-02-10 治疗和预防hiv和aids的方法
CN202110783129.4A Pending CN113509480A (zh) 2016-02-12 2017-02-10 治疗和预防hiv和aids的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110783129.4A Pending CN113509480A (zh) 2016-02-12 2017-02-10 治疗和预防hiv和aids的方法

Country Status (37)

Country Link
US (4) US10537589B2 (cg-RX-API-DMAC7.html)
EP (1) EP3413897B1 (cg-RX-API-DMAC7.html)
JP (4) JP6810972B2 (cg-RX-API-DMAC7.html)
KR (4) KR20220126787A (cg-RX-API-DMAC7.html)
CN (2) CN108697727A (cg-RX-API-DMAC7.html)
AU (3) AU2017217656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018016349A2 (cg-RX-API-DMAC7.html)
CA (1) CA3013473C (cg-RX-API-DMAC7.html)
CL (1) CL2018002150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3413897T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000183A (cg-RX-API-DMAC7.html)
EA (1) EA201891814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2953535T3 (cg-RX-API-DMAC7.html)
FI (1) FI3413897T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20217231B (cg-RX-API-DMAC7.html)
HR (1) HRP20230935T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063532T2 (cg-RX-API-DMAC7.html)
IL (1) IL260874B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170038B1 (cg-RX-API-DMAC7.html)
LT (1) LT3413897T (cg-RX-API-DMAC7.html)
MD (1) MD3413897T2 (cg-RX-API-DMAC7.html)
MX (3) MX390604B (cg-RX-API-DMAC7.html)
MY (1) MY197090A (cg-RX-API-DMAC7.html)
NI (1) NI201800083A (cg-RX-API-DMAC7.html)
NZ (1) NZ745065A (cg-RX-API-DMAC7.html)
PH (1) PH12018501712A1 (cg-RX-API-DMAC7.html)
PL (1) PL3413897T3 (cg-RX-API-DMAC7.html)
PT (1) PT3413897T (cg-RX-API-DMAC7.html)
RS (1) RS64448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201806783WA (cg-RX-API-DMAC7.html)
SI (1) SI3413897T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005733A (cg-RX-API-DMAC7.html)
TN (1) TN2018000267A1 (cg-RX-API-DMAC7.html)
TW (3) TWI822652B (cg-RX-API-DMAC7.html)
UA (1) UA126375C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017139519A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805073B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194959A (zh) * 2018-12-20 2021-07-30 默沙东公司 Nrtti化合物的新型结晶形式

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
EP4358968A4 (en) * 2021-06-22 2025-05-07 Rome Therapeutics, Inc. 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050277616A1 (en) * 1995-06-07 2005-12-15 Howard Owens Thymine nucleosides with anti-hepatitis B virus activity
US7339053B2 (en) * 2004-03-24 2008-03-04 Yamasa Corporation 4′-C-substituted-2-haloadenosine derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110079783A (ko) 2003-02-19 2011-07-07 예일 유니버시티 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
EP3471829A4 (en) * 2016-06-20 2020-01-15 Merck Sharp & Dohme Corp. ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
US20230149296A1 (en) * 2020-05-05 2023-05-18 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050277616A1 (en) * 1995-06-07 2005-12-15 Howard Owens Thymine nucleosides with anti-hepatitis B virus activity
US7339053B2 (en) * 2004-03-24 2008-03-04 Yamasa Corporation 4′-C-substituted-2-haloadenosine derivative
US20080153774A1 (en) * 2004-03-24 2008-06-26 Satoru Kohgo 4' -C-substituted-2-haloadenosine derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHERYL A. STODDART ET AL: "Oral Administration of the Nucleoside EFdA (4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
MICHAEL MURPHEY-CORB,ET AL.: "Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4-Ethynyl-2-Fluoro-2-Deoxyadenosine In Vitro and In Vivo", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194959A (zh) * 2018-12-20 2021-07-30 默沙东公司 Nrtti化合物的新型结晶形式

Also Published As

Publication number Publication date
US20250073254A1 (en) 2025-03-06
JP7559175B2 (ja) 2024-10-01
TWI822652B (zh) 2023-11-21
FI3413897T3 (fi) 2023-08-25
RS64448B1 (sr) 2023-09-29
CA3013473A1 (en) 2017-08-17
GEP20207190B (en) 2020-12-10
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
JP7021314B2 (ja) 2022-02-16
MY197090A (en) 2023-05-24
JP6810972B2 (ja) 2021-01-13
MX2022002924A (es) 2022-12-15
KR20210049201A (ko) 2021-05-04
TW201731514A (zh) 2017-09-16
KR20220126787A (ko) 2022-09-16
JP2021001189A (ja) 2021-01-07
GEP20217231B (en) 2021-03-25
WO2017139519A1 (en) 2017-08-17
KR20180108815A (ko) 2018-10-04
JP2022062170A (ja) 2022-04-19
AU2022201686A1 (en) 2022-03-31
TW202417010A (zh) 2024-05-01
TWI911551B (zh) 2026-01-11
DK3413897T3 (da) 2023-09-18
LT3413897T (lt) 2023-08-25
US20220331350A1 (en) 2022-10-20
US20200101098A1 (en) 2020-04-02
JP7559175B6 (ja) 2024-10-22
CA3013473C (en) 2021-10-26
EP3413897B1 (en) 2023-06-14
EA201891814A1 (ru) 2019-01-31
JP2019504857A (ja) 2019-02-21
IL260874B2 (en) 2023-10-01
US20180055867A1 (en) 2018-03-01
MX390604B (es) 2025-03-20
AU2017217656A1 (en) 2018-08-23
AU2020202866A1 (en) 2020-05-21
IL260874A (cg-RX-API-DMAC7.html) 2018-09-20
MD3413897T2 (ro) 2023-11-30
HRP20230935T1 (hr) 2023-11-24
UA126375C2 (uk) 2022-09-28
ES2953535T3 (es) 2023-11-14
MX2022002925A (es) 2023-02-10
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
HUE063532T2 (hu) 2024-01-28
AU2020202866B2 (en) 2022-04-07
KR20250136420A (ko) 2025-09-16
PT3413897T (pt) 2023-08-28
SV2018005733A (es) 2018-12-14
TW202610660A (zh) 2026-03-16
NZ784982A (en) 2025-03-28
TN2018000267A1 (en) 2020-01-16
US11337991B2 (en) 2022-05-24
DOP2018000183A (es) 2018-12-31
GEAP202014873A (en) 2020-07-27
EP3413897A1 (en) 2018-12-19
BR112018016349A2 (pt) 2018-12-26
CN113509480A (zh) 2021-10-19
PL3413897T3 (pl) 2023-10-02
SI3413897T1 (sl) 2023-11-30
US12171776B2 (en) 2024-12-24
SG11201806783WA (en) 2018-09-27
MX2018009763A (es) 2018-11-29
ZA201805073B (en) 2019-05-29
PH12018501712A1 (en) 2019-05-15
HK1257347A1 (en) 2019-10-18
JP2024001206A (ja) 2024-01-09
KR102317570B1 (ko) 2021-10-25
NZ745065A (en) 2023-11-24
IL260874B1 (en) 2023-06-01
AU2022201686B2 (en) 2024-08-08
JOP20170038B1 (ar) 2021-08-17

Similar Documents

Publication Publication Date Title
US12171776B2 (en) Methods for treatment and prophylaxis of HIV and AIDS
HK40054462A (en) Methods for treatment and prophylaxis of hiv and aids
EP3823632B1 (en) Efda in combination with doravirine for use in treating f227c mutated hiv infections
EA042565B1 (ru) СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа
HK1257347B (en) Methods for treatment and prophylaxis of hiv and aids
US7745455B2 (en) Zalcitabine (ddC) boosted lamivudine (3TC) compositions for antiretroviral therapy
CA3146263A1 (en) Hiv pre-exposure prophylaxis
CA3054822A1 (en) Hiv post-exposure prophylaxis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220902

Address after: new jersey

Applicant after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Applicant before: MERCK SHARP & DOHME Corp.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20181023

RJ01 Rejection of invention patent application after publication